Galera Therapeutics, Inc.

Equities

GRTX

US36338D1081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
0.196 ^USD	+10.11%		0.00%	+34.80%

04-03	North American Morning Briefing : Powell Awaited -2-	DJ
03-28	Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Galera Therapeutics, Inc. Appoints Christopher Degnan as Chief Financial Officer, Effective October 21, 2019

October 10, 2019 at 10:02 pm

Galera Therapeutics, Inc. announced that Christopher Degnan has been named Chief Financial Officer, effective October 21, 2019. Mr. Degnan recently served as Chief Financial Officer at Verrica Pharmaceuticals.

Latest news about Galera Therapeutics, Inc.

North American Morning Briefing : Powell Awaited -2-	04-03	DJ
Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Galera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
North American Morning Briefing : Markets on Hold -2-	03-20	DJ
North American Morning Briefing : Stock Futures -2-	03-13	DJ
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Galera Therapeutics Announces Review of Strategic Alternatives	31/10/23	CI
Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial	31/10/23	DJ
Galera Therapeutics, Inc. Announces Receipt of Type A Meeting Minutes and Strategic Update	31/10/23	CI
North American Morning Briefing : Treasury Yields -2-	17/08/23	DJ
HC Wainwright Downgrades Galera Therapeutics to Neutral From Buy, Adjusts Price Target to $0.30 From $6	16/08/23	MT
Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
North American Morning Briefing : Stock Futures -2-	11/08/23	DJ
Galera Therapeutics, Inc. Approves Reduction in the Company's Current Workforce by 22 Employees, or Approximately 70% of the Company's Headcount	10/08/23	CI
Galera Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration	10/08/23	CI
Galera Therapeutics, Inc. Announces Elimination of Mark Bachleda, Pharm.D., Chief Commercial Officer	10/08/23	CI
Piper Sandler Downgrades Galera Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.50 From $6	10/08/23	MT
Galera shares tank after US FDA declines to approve inflammation disease drug	09/08/23	RE
Stocks to Watch : Applovin, Disney, Galera Therapeutics	09/08/23	DJ
Galera Therapeutics to Reduce Workforce by 70% to Extend Cash Runway	09/08/23	DJ
Galera Therapeutics, Inc. Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting	05/06/23	CI
Sector Update: Health Care Stocks Slipping Late Tuesday	30/05/23	MT
Galera Therapeutics Sues Alira Health Clinical, IQVIA Biotech Over Alleged Error for Drug Trial	30/05/23	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	30/05/23	MT
Sector Update: Health Care	30/05/23	MT

Chart Galera Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Companyâs lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Companyâs second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
GALERA THERAPEUTICS, INC.	+34.80%	9.68M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B

Bio Therapeutic Drugs